Drugs / Fenoldopam
Fenoldopam
also known as
Carlacor · Corlopam · Fendolopam mesylate · FENOLDOPAM BROMIDE · Fenoldopam mesilate · Fenoldopam mesylate · Fenoldopam methanesulfonate · NSC-759860 · +4 more
Small molecule targets DRD1 via activation
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | CORLOPAM | — | 2004-04-01 | fda.gov ↗ |
| Approved | US (FDA) | CORLOPAM | — | 1997-09-23 | fda.gov ↗ |
Trials 10 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00592150 | Jun 2007 → Mar 2008 | essential hypertension | University of Virginia | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00467181 | Jan 2005 → Apr 2006 | — | Summa Health System | Completed | No outcome recorded |
| Phase 2 | NCT00122018 | May 2002 → Mar 2006 | acute kidney injury, chronic renal failure syndrome | Linda F. Barr, M.D. | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT02620761 | Feb 2019 → Jan 2020 | acute kidney injury, patent ductus arteriosus | Medical College of Wisconsin | Terminated | No outcome recorded |
| Phase 2/3 | NCT00286403 | Aug → Oct 2008 | acute kidney injury | Southeast Renal Research Institute | Withdrawn | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT00557219 | Apr 2008 → Apr 2015 | acute kidney injury | Medical University of Gdansk | Terminated | No outcome recorded |
| Phase 3 | NCT00621790 | Feb 2008 → Jun 2013 | acute kidney injury | Vita-Salute San Raffaele University | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT01073189 | Apr 2010 → Jan 2011 | acute kidney injury | Southeast Renal Research Institute | Withdrawn | No outcome recorded |
| Phase 4 | NCT00747331 | Sep 2008 → Apr 2009 | cardiovascular disorder | IRCCS Policlinico S. Donato | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01324245 | Nov 2002 → Dec 2005 | hypertensive disorder | Georgetown University | Completed | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT00982527 Comparator | Sep 2009 → Sep 2010 | acute kidney injury | Bambino Gesù Hospital and Research Institute | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01690832 Comparator | Sep 2012 → Dec 2013 | coronary artery disorder | University of Roma La Sapienza | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00743106 Comparator | Sep 2002 → Feb 2010 | — | The Cleveland Clinic | Terminated | No outcome recorded |
Evidence & citations 17 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fenoldopam | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00747331 ↗ |
| Known as | Carlacor | ChEMBL registry synonym — accepted as the source's own label CHEMBL588 ↗ |
| Known as | Corlopam | “fenoldopam (Corlopam)” NCT00557219 ↗ |
| Known as | Fendolopam mesylate | ChEMBL registry synonym — accepted as the source's own label CHEMBL588 ↗ |
| Known as | FENOLDOPAM BROMIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL588 ↗ |
| Known as | Fenoldopam mesilate | “Fenoldopam mesilate is a selective splanchnic vasodilator when used at a dose \< 0.1 mcg/kg/min.” NCT00747331 ↗ |
| Known as | Fenoldopam mesylate | “Fenoldopam mesylate is a short-acting dopamine-1 agonist that has been suggested to be a possible reno-protective agent in patients undergoing cardiac surgery.” PMID 20332738 ↗ Apr 2010 |
| Known as | Fenoldopam methanesulfonate | ChEMBL registry synonym — accepted as the source's own label CHEMBL588 ↗ |
| Known as | NSC-759860 | ChEMBL registry synonym — accepted as the source's own label CHEMBL588 ↗ |
| Known as | SK&F 82526-J | ChEMBL registry synonym — accepted as the source's own label CHEMBL588 ↗ |
| Known as | SK&F-82526 | ChEMBL registry synonym — accepted as the source's own label CHEMBL588 ↗ |
| Known as | SK-82526 | ChEMBL registry synonym — accepted as the source's own label CHEMBL588 ↗ |
| Known as | SK-82526-J | ChEMBL registry synonym — accepted as the source's own label CHEMBL588 ↗ |
| Action | Activate | “Fenoldopam is a short-acting benzazepine selective dopaminergic A1 (DA1) receptor agonist with increased activity at the D1 receptor compared with dopamine.” PMID 39607014 ↗ Nov 20241“Dopamine D1 receptor agonist” CHEMBL588 ↗ |
| Modality | Small molecule | “Fenoldopam is a short-acting benzazepine selective dopaminergic A1 (DA1) receptor agonist with increased activity at the D1 receptor compared with dopamine.” PMID 39607014 ↗ Nov 2024 |
| Route | Intravenous | “fenoldopam 0.1 mcg/kg/min intravenous (IV) or saline placebo at anesthetic induction and continuing for 48 hours” NCT00122018 ↗ |
| Target | DRD1 | “Dopamine D1 receptor agonist” CHEMBL588 ↗ |